Nemolizumab is currently in development for atopic dermatitis and prurigo nodularis. Atopic dermatitis is the most common form of eczema, a long-term (chronic) condition that causes patches of the skin to become itchy, dry and cracked. In moderate-to-severe cases, the patches cover a large area of the skin and can be associated with an intense […]
Baricitinib is currently in clinical development for the treatment of moderate-to-severe atopic dermatitis (AD) in children and adolescents. AD is a common, long-term (chronic) inflammatory skin condition that results in patches of redness, itchiness, and scaling of the skin. In moderate-to-severe cases of AD, the patches cover a large area of the skin and can […]
Upadacitinib is in development for the treatment of moderate to severe atopic dermatitis (AD). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin […]
Tralokinumab is proposed for the treatment of moderate to severe atopic dermatitis (AD) in adolescent patients (12-17 years old). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may […]
Tralokinumab is in development for the treatment of moderate to severe atopic dermatitis (AD) uncontrolled with currently available therapies in adult patients who are candidates for systematic therapy. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only […]
Lebrikizumab is being developed for patients (aged 12 years to adult) with moderate to severe atopic dermatitis (AD). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience […]
Dupilumab is in development for the treatment of children aged 6 up to 12 years with severe atopic dermatitis (AD) uncontrolled with currently available therapies. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches […]
Baricitinib is in development for the treatment of adults with moderate to severe atopic dermatitis (AD) which is also known as eczema or atopic eczema. AD is a chronic inflammatory skin disease that affects both children and adults and is characterized by redness, itchiness, and scaling of the skin. Some people only have small patches […]
Atopic dermatitis (AD) or atopic eczema is a very common skin condition due to skin inflammation. It is usually a long-term condition where the skin becomes itchy, dry, cracked, sore and red. About one in every five children in the UK have AD. This condition may have impacts on the affected child’s quality of life. […]
Abrocitinib is in development for the treatment of moderate to severe atopic dermatitis (AD) in adolescents and adults aged 12 years or over. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry […]
